Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

Agree Pete. In comparing the phase2b study Dr Jorgensen stated that B as a single dose was comparable to daptomycin's 7 day regimen so clearly B has a strong anti-bacterial quality. Looking forward to hearing more on the ant-fungal results.

“We worked with the FDA in designing the recent phase 2b study,” said Dr. Jorgensen. ” As predicted, a lower total dose of Brilacidin, given as a single-dose regimen, was well tolerated and efficacy was comparable to that of the 7-day regimen of the active control, daptomycin.”

“It’s important to note that a single-dose regimen has benefits beyond safety and efficacy,” Dr. Jorgensen added. ”It can maximize patient compliance and thereby reduce the potential for the development of antibiotic resistance. Of course, Brilacidin’s unique mechanism of action to penetrate the bacterial cell wall to eradicate bacteria is another reason why resistance is unlikely to develop. Further, Brilacidin has anti-inflammatory and anti-biofilm properties. When considering all these factors, Brilacidin has the potential to transform the way we treat infectious diseases.”